Drug
Resmetirom
Resmetirom: highest development phase Phase 3, developed by Madrigal Pharmaceuticals. 7 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Madrigal Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Resmetirom NCT04197479 | Phase 3 | Non-Alcoholic Fatty Liver Disease |
| Resmetirom NCT05500222 | Phase 3 | NASH |
| Resmetirom NCT04951219 | Phase 3 | Non-Alcoholic Fatty Liver Disease |
| Resmetirom NCT07763015 | Phase 2 | MASH |
| Resmetirom NCT07335601 | Phase 2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis |
| 100 mg Resmetirom Tablet NCT06397872 | Phase 1 | Renal Impairment |
| Resmetirom NCT07830758 | Phase 1 | MASH - Metabolic Dysfunction-Associated Steatohepatitis |
Latest
No recent events.
Follow Resmetirom on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.